FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199451569> ?p ?o ?g. }

• W3199451569 abstract "Objective: Establish the efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate, LXB; Xywav™; previously designated as JZP-258) in a double-blind randomized withdrawal study in adults with narcolepsy with cataplexy. Health-related quality of life (HRQoL) endpoints from this study are presented. Background: Narcolepsy negatively impacts HRQoL. Sodium oxybate (Xyrem®) is a standard of care for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy. LXB is an oxybate medication with 92% less sodium. Design/Methods: Participants 18–70 years of age began LXB treatment during a 12-week, open-label, optimized treatment and titration period, followed by a 2-week stable-dose period. Participants were then randomized to receive placebo or continue LXB treatment during a 2-week, double-blind, randomized withdrawal period. HRQoL assessments included the 36-Item Short Form Health Survey Version 2 (SF-36) and 5-level EuroQoL 5-Dimensions Self-Report Questionnaire (EQ-5D-5L). Results: 201 participants enrolled; 134 were randomized and received at least 1 dose of double-blind study medication (efficacy population; placebo, n=65; LXB, n=69). Decreased scores (worsening) were observed in participants randomized to placebo compared with participants randomized to continue LXB treatment for the SF-36 physical component summary (median [Q1, Q3], −1.92 [−3.46, 1.73] for placebo and −0.03 [−2.07, 2.41] for LXB; nominal P=0.02), SF-36 mental component summary (−1.92 [−6.28, 1.34] for placebo and 1.55 [−1.88, 3.78] for LXB; nominal P=0.03), and EQ-5D-5L visual analog scale (−5.0 [−10.0, 5.0] for placebo and 0.0 [0.0, 5.0] for LXB; nominal P=0.0056). No change was observed in the EQ-5D-5L crosswalk index (0.00 [−0.05, 0.03] for placebo and 0.00 [−0.01, 0.03] for LXB; nominal P=0.3918). The overall safety profile of LXB was similar to sodium oxybate. Conclusions: HRQoL worsened in those randomized to placebo during the 2-week double-blind randomized withdrawal period but remained stable in participants who continued LXB treatment. Disclosure: Dr. Foldvary-Schaefer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Thorpy has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Harmony biosciences. Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai . Dr. Roy has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Inspire. The institution of Dr. Roy has received research support from Jazz . The institution of Dr. Roy has received research support from Inspire. The institution of Dr. Roy has received research support from Avadel. Lihua Tang has nothing to disclose. Dr. Skowronski has nothing to disclose. Karel Sonka has received personal compensation for serving as an employee of Jazz. Karel Sonka has received personal compensation for serving as an employee of Flamel-Avadel. Karel Sonka has received personal compensation for serving as an employee of Luitpold Pharmaceutical. Karel Sonka has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Karel Sonka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Karel Sonka has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Angelini. Karel Sonka has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Stada. Karel Sonka has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Richard K. Bogan, MD has nothing to disclose." @default.
• W3199451569 created "2021-09-27" @default.
• W3199451569 creator A5008480675 @default.
• W3199451569 creator A5014966950 @default.
• W3199451569 creator A5038093846 @default.
• W3199451569 creator A5045293371 @default.
• W3199451569 creator A5070041246 @default.
• W3199451569 creator A5084367532 @default.
• W3199451569 creator A5088687426 @default.
• W3199451569 creator A5090559311 @default.
• W3199451569 date "2021-04-13" @default.
• W3199451569 modified "2023-09-28" @default.
• W3199451569 title "Quality of Life in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Narcolepsy With Cataplexy (2044)" @default.
• W3199451569 hasPublicationYear "2021" @default.
• W3199451569 type Work @default.
• W3199451569 sameAs 3199451569 @default.
• W3199451569 citedByCount "0" @default.
• W3199451569 crossrefType "journal-article" @default.
• W3199451569 hasAuthorship W3199451569A5008480675 @default.
• W3199451569 hasAuthorship W3199451569A5014966950 @default.
• W3199451569 hasAuthorship W3199451569A5038093846 @default.
• W3199451569 hasAuthorship W3199451569A5045293371 @default.
• W3199451569 hasAuthorship W3199451569A5070041246 @default.
• W3199451569 hasAuthorship W3199451569A5084367532 @default.
• W3199451569 hasAuthorship W3199451569A5088687426 @default.
• W3199451569 hasAuthorship W3199451569A5090559311 @default.
• W3199451569 hasConcept C118552586 @default.
• W3199451569 hasConcept C126322002 @default.
• W3199451569 hasConcept C142724271 @default.
• W3199451569 hasConcept C159110408 @default.
• W3199451569 hasConcept C168563851 @default.
• W3199451569 hasConcept C1862650 @default.
• W3199451569 hasConcept C204787440 @default.
• W3199451569 hasConcept C27081682 @default.
• W3199451569 hasConcept C2779494582 @default.
• W3199451569 hasConcept C2779951463 @default.
• W3199451569 hasConcept C2780163352 @default.
• W3199451569 hasConcept C2780714222 @default.
• W3199451569 hasConcept C2908647359 @default.
• W3199451569 hasConcept C42219234 @default.
• W3199451569 hasConcept C71924100 @default.
• W3199451569 hasConcept C99454951 @default.
• W3199451569 hasConceptScore W3199451569C118552586 @default.
• W3199451569 hasConceptScore W3199451569C126322002 @default.
• W3199451569 hasConceptScore W3199451569C142724271 @default.
• W3199451569 hasConceptScore W3199451569C159110408 @default.
• W3199451569 hasConceptScore W3199451569C168563851 @default.
• W3199451569 hasConceptScore W3199451569C1862650 @default.
• W3199451569 hasConceptScore W3199451569C204787440 @default.
• W3199451569 hasConceptScore W3199451569C27081682 @default.
• W3199451569 hasConceptScore W3199451569C2779494582 @default.
• W3199451569 hasConceptScore W3199451569C2779951463 @default.
• W3199451569 hasConceptScore W3199451569C2780163352 @default.
• W3199451569 hasConceptScore W3199451569C2780714222 @default.
• W3199451569 hasConceptScore W3199451569C2908647359 @default.
• W3199451569 hasConceptScore W3199451569C42219234 @default.
• W3199451569 hasConceptScore W3199451569C71924100 @default.
• W3199451569 hasConceptScore W3199451569C99454951 @default.
• W3199451569 hasOpenAccess W3199451569 @default.
• W3199451569 hasRelatedWork W2801706337 @default.
• W3199451569 hasRelatedWork W2802731780 @default.
• W3199451569 hasRelatedWork W2803651213 @default.
• W3199451569 hasRelatedWork W2803956198 @default.
• W3199451569 hasRelatedWork W2804412694 @default.
• W3199451569 hasRelatedWork W2808054523 @default.
• W3199451569 hasRelatedWork W2811297374 @default.
• W3199451569 hasRelatedWork W2885049414 @default.
• W3199451569 hasRelatedWork W2893281143 @default.
• W3199451569 hasRelatedWork W2894489394 @default.
• W3199451569 hasRelatedWork W2962303456 @default.
• W3199451569 hasRelatedWork W3019112891 @default.
• W3199451569 hasRelatedWork W3043068731 @default.
• W3199451569 hasRelatedWork W3086841210 @default.
• W3199451569 hasRelatedWork W3139500862 @default.
• W3199451569 hasRelatedWork W3159402725 @default.
• W3199451569 hasRelatedWork W3161104252 @default.
• W3199451569 hasRelatedWork W3174992356 @default.
• W3199451569 hasRelatedWork W3183081226 @default.
• W3199451569 hasRelatedWork W3198538026 @default.
• W3199451569 hasVolume "96" @default.
• W3199451569 isParatext "false" @default.
• W3199451569 isRetracted "false" @default.
• W3199451569 magId "3199451569" @default.
• W3199451569 workType "article" @default.